EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

Joseph J Sacco iD, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari iD, Jessica C Hassel iD, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matthew Rioth, Douglas B Johnson und 6 weitere

Journal for ImmunoTherapy of Cancer · 2024-06 · 12 (6) · e009028

DOI: 10.1136/jitc-2024-009028 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.06.2024. Verfasst von Joseph J Sacco und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK joseph.sacco@nhs.net Takami.Sato@jefferson.edu. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Immunocore Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of study IMCgp100-102. Here we report long-term outcomes from this phase 1/2 study in pretreated mUM. Patients and methods Patients with previously treated mUM received tebentafusp weekly intravenous at 20 µg dose 1, 30 µg dose 2 and either 54, 64, 68, or 73 µg (phase 1) or 68 µg (phase 2) dose 3+. The primary objective was overall response rate. Secondary objectives included OS and safety. OS was estimated by Kaplan-Meier methods. Association between OS and baseline covariates, on-treatment Response Evaluation Criteria in Solid Tumors (RECIST) response, baseline tumor biopsy and circulating-tumor DNA (ctDNA) changes were assessed.

Results

146 patients were treated with tebentafusp: 19 in phase 1 and 127 in phase 2. With a median follow-up duration of 48.5 months, the median OS was 17.4 months (95% CI, 13.1 to 22.8), and the 1-year, 2-year, 3-year and 4-year OS rates were 62%, 40%, 23% and 14%, respectively. Improved survival was associated with lower ctDNA baseline levels and greater ctDNA reductions by week 9 on-treatment, with 100% 1-year, 73% 2-year and 45% 3-year OS rates for patients with ctDNA clearance. Baseline gp100 expression was not associated with survival, despite more RECIST responses among patients with higher expression. No new safety signals were reported with long-term dosing.

Conclusions

This study represents the longest follow-up of a Tcell receptor bispecific to date and confirms the durable survival benefits achieved with tebentafusp in previously treated mUM with good tolerability long-term. A role for ctDNA reduction as an early indicator of clinical benefit was again suggested for patients treated with tebentafusp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaUveal NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultFollow-Up StudiesAntibodies, BispecificAged, 80 and overNeoplasm MetastasisUveal Melanoma

Stichwörter der Autor:innen

T cell receptor - TCRbispecific T cell engager - BiTEcirculating tumor DNA - ctDNAimmunotherapysolid tumor

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK joseph.sacco@nhs.net Takami.Sato@jefferson.edu.
  • University of Liverpool, Liverpool, Merseyside, UK.
  • Northwell Health Cancer Institute, New York, New York, USA.
  • Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York, USA.
  • Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
  • Department of Medicine, Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Joseph J Sacco, Alexander N Shoushtari, Jessica C Hassel, Jason J Luke

Förderung

  • NCI NIH HHS
  • Immunocore Ltd

Zitieren

APA

Sacco, J. J., Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Holland, C., & Sato, T. (2024). Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for ImmunoTherapy of Cancer, 12(6), e009028. https://doi.org/10.1136/jitc-2024-009028

Vancouver

Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, et al. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for ImmunoTherapy of Cancer. 2024;12(6):e009028. doi:10.1136/jitc-2024-009028

BibTeX
@article{Sacco2024,
  author = {Sacco, Joseph J and Carvajal, Richard D and Butler, Marcus O and Shoushtari, Alexander N and Hassel, Jessica C and Ikeguchi, Alexandra and Hernandez-Aya, Leonel and Nathan, Paul and Hamid, Omid and Piulats, Josep M and Rioth, Matthew and Johnson, Douglas B and Luke, Jason J and Espinosa, Enrique and Leyvraz, Serge and Collins, Laura and Holland, Chris and Sato, Takami},
  title = {Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {6},
  pages = {e009028},
  doi = {10.1136/jitc-2024-009028}
}
Kostenlos starten →